CN105218678A - 重组结核杆菌esat6-cfp10融合蛋白及其制备方法 - Google Patents
重组结核杆菌esat6-cfp10融合蛋白及其制备方法 Download PDFInfo
- Publication number
- CN105218678A CN105218678A CN201510617780.9A CN201510617780A CN105218678A CN 105218678 A CN105218678 A CN 105218678A CN 201510617780 A CN201510617780 A CN 201510617780A CN 105218678 A CN105218678 A CN 105218678A
- Authority
- CN
- China
- Prior art keywords
- esat6
- cfp10
- recombinant
- pet
- fusion rotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000193830 Bacillus <bacterium> Species 0.000 title claims abstract description 61
- 108700014461 ESAT-6-CFP10 fusion Proteins 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 101150079015 esxB gene Proteins 0.000 claims abstract description 18
- 230000001580 bacterial effect Effects 0.000 claims abstract description 11
- 230000014509 gene expression Effects 0.000 claims abstract description 10
- 230000009465 prokaryotic expression Effects 0.000 claims abstract description 7
- 238000000746 purification Methods 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 6
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 6
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 6
- 241000588722 Escherichia Species 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 46
- 239000013612 plasmid Substances 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 241000588724 Escherichia coli Species 0.000 claims description 18
- 230000029087 digestion Effects 0.000 claims description 16
- 108091008146 restriction endonucleases Proteins 0.000 claims description 14
- 238000012797 qualification Methods 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 208000032420 Latent Infection Diseases 0.000 abstract description 9
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 238000001514 detection method Methods 0.000 abstract description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 27
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 25
- 241000700199 Cavia porcellus Species 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 14
- 201000008827 tuberculosis Diseases 0.000 description 10
- 239000007788 liquid Substances 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000005951 type IV hypersensitivity Effects 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 208000003643 Callosities Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 241000186364 Mycobacterium intracellulare Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000011554 guinea pig model Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002706 plastid Anatomy 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 229940070741 purified protein derivative of tuberculin Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000009146 rhinoscleroma Diseases 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 1
- 101100008046 Caenorhabditis elegans cut-2 gene Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
- 108091034946 ESAT-6 family Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108700020164 Mycobacterium tuberculosis ESAT-6 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510617780.9A CN105218678B (zh) | 2015-09-23 | 2015-09-23 | 重组结核杆菌esat6-cfp10融合蛋白及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510617780.9A CN105218678B (zh) | 2015-09-23 | 2015-09-23 | 重组结核杆菌esat6-cfp10融合蛋白及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105218678A true CN105218678A (zh) | 2016-01-06 |
CN105218678B CN105218678B (zh) | 2019-05-07 |
Family
ID=54988002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510617780.9A Active CN105218678B (zh) | 2015-09-23 | 2015-09-23 | 重组结核杆菌esat6-cfp10融合蛋白及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105218678B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108440656A (zh) * | 2018-03-08 | 2018-08-24 | 中国医学科学院病原生物学研究所 | 结核分枝杆菌pka蛋白及其融合蛋白在辅助诊断肺结核病中的应用 |
CN110423279A (zh) * | 2019-06-20 | 2019-11-08 | 扩增生物科技(北京)有限公司 | 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用 |
CN110684116A (zh) * | 2019-08-23 | 2020-01-14 | 北京恩元华生物科技有限公司 | 一种结核分枝杆菌eec融合蛋白、制备方法及其应用 |
CN111269297A (zh) * | 2020-01-23 | 2020-06-12 | 郑州伊美诺生物技术有限公司 | 一种结核分枝杆菌刺激抗原的制备方法 |
CN111655734A (zh) * | 2019-04-28 | 2020-09-11 | 广州市雷德生物科技有限公司 | 一种促进蛋白二聚体形成的拉链扣结构及其应用 |
WO2020221153A1 (zh) * | 2019-04-28 | 2020-11-05 | 广州市雷德生物科技有限公司 | 一种促进蛋白二聚体形成的拉链扣结构及其应用 |
CN113045677A (zh) * | 2021-05-06 | 2021-06-29 | 北京祥瑞生物制品有限公司 | 一种重组融合蛋白及其在结核诊断中应用 |
WO2023179592A1 (zh) * | 2022-03-22 | 2023-09-28 | 安博智联(北京)生物科技有限公司 | 结核分枝杆菌特异性的重组融合蛋白e35及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101221173A (zh) * | 2007-01-12 | 2008-07-16 | 中国人民解放军总医院第二附属医院 | ELISpot结核感染诊断试剂盒及其应用 |
CN101455847A (zh) * | 2007-12-12 | 2009-06-17 | 中国人民解放军总医院第二附属医院 | Esat6和cfp10蛋白在制备用于鉴定诊断结核病的药物中的应用 |
-
2015
- 2015-09-23 CN CN201510617780.9A patent/CN105218678B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101221173A (zh) * | 2007-01-12 | 2008-07-16 | 中国人民解放军总医院第二附属医院 | ELISpot结核感染诊断试剂盒及其应用 |
CN101455847A (zh) * | 2007-12-12 | 2009-06-17 | 中国人民解放军总医院第二附属医院 | Esat6和cfp10蛋白在制备用于鉴定诊断结核病的药物中的应用 |
Non-Patent Citations (3)
Title |
---|
蒲江等: "重组结核分枝杆菌ESAT6-CFP10蛋白对不同分枝杆菌致敏豚鼠的皮试反应研究", 《中国防痨杂志》 * |
袁勤生: "《酶与酶工程》", 31 August 2012 * |
闫璐颖等: "融合蛋白连接肽的研究进展", 《生物技术》 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108440656A (zh) * | 2018-03-08 | 2018-08-24 | 中国医学科学院病原生物学研究所 | 结核分枝杆菌pka蛋白及其融合蛋白在辅助诊断肺结核病中的应用 |
CN108440656B (zh) * | 2018-03-08 | 2020-04-17 | 中国医学科学院病原生物学研究所 | 结核分枝杆菌pka蛋白及其融合蛋白在辅助诊断肺结核病中的应用 |
CN111655734A (zh) * | 2019-04-28 | 2020-09-11 | 广州市雷德生物科技有限公司 | 一种促进蛋白二聚体形成的拉链扣结构及其应用 |
WO2020221153A1 (zh) * | 2019-04-28 | 2020-11-05 | 广州市雷德生物科技有限公司 | 一种促进蛋白二聚体形成的拉链扣结构及其应用 |
CN110423279A (zh) * | 2019-06-20 | 2019-11-08 | 扩增生物科技(北京)有限公司 | 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用 |
CN110423279B (zh) * | 2019-06-20 | 2021-07-27 | 扩增生物科技(北京)有限公司 | 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用 |
CN110684116A (zh) * | 2019-08-23 | 2020-01-14 | 北京恩元华生物科技有限公司 | 一种结核分枝杆菌eec融合蛋白、制备方法及其应用 |
CN110684116B (zh) * | 2019-08-23 | 2022-04-26 | 成都可恩生物科技有限公司 | 一种结核分枝杆菌eec融合蛋白、制备方法及其应用 |
CN111269297A (zh) * | 2020-01-23 | 2020-06-12 | 郑州伊美诺生物技术有限公司 | 一种结核分枝杆菌刺激抗原的制备方法 |
CN111269297B (zh) * | 2020-01-23 | 2021-11-30 | 郑州伊美诺生物技术有限公司 | 一种结核分枝杆菌刺激抗原的制备方法 |
CN113045677A (zh) * | 2021-05-06 | 2021-06-29 | 北京祥瑞生物制品有限公司 | 一种重组融合蛋白及其在结核诊断中应用 |
WO2023179592A1 (zh) * | 2022-03-22 | 2023-09-28 | 安博智联(北京)生物科技有限公司 | 结核分枝杆菌特异性的重组融合蛋白e35及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105218678B (zh) | 2019-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105218678A (zh) | 重组结核杆菌esat6-cfp10融合蛋白及其制备方法 | |
CN101221173A (zh) | ELISpot结核感染诊断试剂盒及其应用 | |
CN113980145B (zh) | 一种结核分枝杆菌融合蛋白及其制备方法和应用 | |
CN107216373B (zh) | 检测结核分枝杆菌感染的抗原多肽池及其应用 | |
CN107011418B (zh) | 检测结核分枝杆菌感染的抗原多肽池及其应用 | |
CN113045677A (zh) | 一种重组融合蛋白及其在结核诊断中应用 | |
CN101846677B (zh) | 一种牛结核杆菌抗体免疫胶体金检测试纸条及其制备方法 | |
CN101455847A (zh) | Esat6和cfp10蛋白在制备用于鉴定诊断结核病的药物中的应用 | |
CN105039233B (zh) | 一种牛种布鲁氏菌分子标记疫苗株及其应用 | |
CN101684160A (zh) | 用于牛结核病诊断的重组蛋白及其应用 | |
CN104292315A (zh) | 一种Rv2645蛋白的制备及其在结核诊断与重组BCG疫苗中的应用 | |
CN106435007A (zh) | 一种荧光定量pcr检测猪丹毒杆菌的引物、探针、试剂盒及方法 | |
CN105524177A (zh) | 结核分枝杆菌特异性融合蛋白及其编码基因与应用 | |
CN104805063A (zh) | 结核分枝杆菌潜伏感染相关蛋白及其制备和应用 | |
CN103397023B (zh) | 猪丹毒杆菌的pcr引物及其应用 | |
CN106279381B (zh) | 一种特异性检测结核分枝杆菌感染的蛋白 | |
CN107236023B (zh) | 一种用于检测结核感染的抗原组合物及其应用 | |
CN111303301A (zh) | 一种结核分枝杆菌免疫原蛋白esat6的制备方法 | |
CN106188249A (zh) | 用于检测pedv变异株抗体的抗原及方法和试剂盒 | |
KR20090041663A (ko) | 우결핵균 특이단백질 및 그 정제방법 | |
CN114957487B (zh) | 一种重组结核分枝杆菌融合蛋白及其在结核诊断中应用 | |
CN108276494B (zh) | 结核分枝杆菌变态反应原组合物及其制备方法与应用 | |
CN106405113A (zh) | 一种用于检测潜在结核的特异性标志物及其应用 | |
Wen et al. | Analysis of Genetic Variation of VP2 Gene in 6 FPV Strainsin China | |
CN104371013A (zh) | 牛分枝杆菌cfp-10的迟发型变态反应抗原表位多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180124 Address after: 230088 Hefei high tech Zone, Anhui, No. 100 floating Hill Road Applicant after: ANHUI ZHIFEI LONGCOM BIOPHARMACEUTICAL Co.,Ltd. Applicant after: CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD. Applicant after: BEIJING ZHIFEI LVZHU BIOPHARMACEUTICAL Co.,Ltd. Address before: 230088 Hefei high tech Zone, Anhui, No. 100 floating Hill Road Applicant before: ANHUI ZHIFEI LONGCOM BIOPHARMACEUTICAL Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: 230000, No. 5008 Mingzhu Avenue, Hefei City, Anhui Province Patentee after: ANHUI ZHIFEI LONGCOM BIOPHARMACEUTICAL Co.,Ltd. Patentee after: CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD. Patentee after: BEIJING ZHIFEI LVZHU BIOPHARMACEUTICAL Co.,Ltd. Address before: 230088 No.100 Fushan Road, high tech Zone, Hefei City, Anhui Province Patentee before: ANHUI ZHIFEI LONGCOM BIOPHARMACEUTICAL Co.,Ltd. Patentee before: CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD. Patentee before: BEIJING ZHIFEI LVZHU BIOPHARMACEUTICAL Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |